Vancomycin Dosing in a Patient with Obesity and Acute Kidney Injury
A 55-year-old man (weight 120 kg, height 175 cm, BMI 39.2 kg/m²) is admitted with MRSA bacteremia and acute kidney injury (AKI). Serum creatinine is 2.8 mg/dL (baseline 0.9 mg/dL), and he is oliguric. He is started on vancomycin. The pharmacy team must design an initial dosing regimen, recommend monitoring, and adjust for renal function. The hospital uses AUC-guided dosing with a target AUC24/MIC of 400–600 for MRSA (MIC 1 mg/L).
1. Calculate an appropriate vancomycin loading dose and initial maintenance regimen for this patient, considering his obesity and AKI.
Read the worked answer
For serious MRSA infections, a loading dose of 25–30 mg/kg actual body weight is recommended. Using 25 mg/kg × 120 kg = 3000 mg. However, in obesity, dosing on actual body weight may increase toxicity; some guidelines suggest capping at 3000 mg or using adjusted body weight. A loading dose of 2500–3000 mg IV is reasonable. For maintenance, since he has AKI (CrCl estimated by Cockcroft-Gault: (140-55)×120/(72×2.8) ≈ 50 mL/min, but with oliguria and rising creatinine, true GFR is lower), initial maintenance should be based on renal function. A common approach is to give 15–20 mg/kg (1800–2400 mg) every 24–48 hours, then adjust based on levels. Because of AKI, consider extending interval to 48 hours initially. Obtain a trough before the 4th dose or use Bayesian software. Target AUC24 400–600. Monitor renal function daily.
2. How would you monitor vancomycin therapy and adjust the dose to achieve the target AUC while minimizing nephrotoxicity?
Read the worked answer
Obtain two serum vancomycin concentrations (peak and trough) around the third dose to calculate AUC using a pharmacokinetic model. Alternatively, use a Bayesian approach with a single trough. Monitor serum creatinine daily. Avoid concomitant nephrotoxins (NSAIDs, aminoglycosides, contrast). If AUC is below 400, increase dose or shorten interval; if above 600, reduce dose or lengthen interval. In AKI, consider extending interval rather than increasing dose to avoid high peaks. Target trough 15–20 mg/L if AUC monitoring unavailable. Ensure adequate hydration and monitor urine output. Adjust for renal recovery: as CrCl improves, interval may shorten. Document rationale.